Sirona Biochem (Seite 3096)

[Jon_Schnee]

Zitat von Jon_Schnee: LOI Obagi/Valeant & LOI Wanbang/Fosun China sind nun definitiv.

Fosun ist vermutlich vielen kein Begriff:

Fosun =

Fosun International Limited

Fosun International Limited, auch Fosun oder Fosun International, ist das größte private-Konglomerat in Festland China , [1] mit Sitz in Shanghai (Hong Kong -> incorporated). Es wird auch als "Shanghai Hutchison Whampoa" bezeichnet.

mehr Infos:
http://en.wikipedia.org/wiki/Fosun_International_Limited

[Jon_Schnee]

Antwort auf Beitrag Nr.: 46.349.189 von Jon_Schnee am 31.01.14 07:53:31

LOI Obagi/Valeant & LOI Wanbang/Fosun China sind nun definitiv.

[Jon_Schnee]

Anbei noch die Pipeline von Sirona Biochem. Sie wächst und wächst.

Kosmetik: ist eher kurz bis mittelfristig. Erstes Produkt "Skin Lightening" sollte schon in Q4/2014 auf den Markt kommen.

Pharma: langfristig.

[Jon_Schnee]

Antwort auf Beitrag Nr.: 46.345.065 von manffreddoo am 30.01.14 16:50:10

dann gilt jetzt Daumendrücken!

Werde mich gerne bei Anteo einlesen.

In Kanada werden schon die nächsten LOI besprochen.
Aber zuerst das PP schliessen.

Sonnencreme ist laut Management im Focus, da es schnell auf den Markt kommen könnte. Aber sie müssten dafür ein guten Partner finden - oder er findet Sirona:

http://www.youtube.com/watch?v=FKohVwPejZk#t=0

[manffreddoo]

Antwort auf Beitrag Nr.: 46.341.193 von Jon_Schnee am 30.01.14 10:36:41

Soderle, eben in Ffm gekauft.....0.12.E....Anfangsposi.-----wenn PP nicht läuft, wovon ich nicht ausgehe(bei den namhaften Partnern) kann ich immer noch mit geringem Verlust raus....ansonsten :Zukauf.
Ja Anteo ist gut gelaufen,gemäss unsrer Diskussion und Einschätzung im Anteo Thread dürfte das gerade mal der Anfang gewesen sein........Jon,lies dich da mal ein von Seite 1 an.
Wantedman hat ,so wie du hier(hoffentlich) einen phantastischen Spürsinn entwickelt)
Ansonsten,ein mir bekannter User namens Ahorne würde zu dir und deiner Recherche sagen: WeLL DONE
Gruss
M.

[Jon_Schnee]

Antwort auf Beitrag Nr.: 46.338.941 von manffreddoo am 29.01.14 22:32:52

Hallo manfreddoo

schöner chart:
http://www.bloomberg.com/quote/ADO:AU

ja, ich hoffe Sirona folgt Anteo Diagnostics

[manffreddoo]

...die Ausgangslage scheint mir bei S.B.identisch zu sein mit der von Anteo Diagnostics vor 3 Jahren.Damals bei0,03 austr. cents,heute bei 0,19cts.Werde bei S.B.einsteigen!und long bleiben.........riecht wie bei Anteo nach geduldigen Gewinnen in höheren Regionen........
M.

[Jon_Schnee]

keine Kursreaktion:

E-Mail Antwort auf SH:


Reply from C. Hopton

You’re probably right. Unfortunately we couldn’t really control the timing of the two major deals. Both deals have been in the works for well over a year each – and they get green lighted the same week during a raise! What are the odds.

The reality is we are trading at 150% above our 52 week low and have transitioned from pre-revenue to post-revenue. I think we accomplished a lot in a year.
Yesterday I cut the first invoice ever. It was a great feeling!

Cheers/
Chris



From: Marc
Sent: January-29-14 7:11 AM
To: Christopher Hopton
Subject: Fwd: Sirona Biochem Completes Global Exclusive Licensing Agreement with Obagi Medical Products


Hi Chris,



I think shareholders didn't like the 5,3 millions PP announced just before both deals closed. That means dilution.


Marc

Read more at http://www.stockhouse.com/companies/bullboard/v.sbm/sirona-b…

[Jon_Schnee]

Antwort auf Beitrag Nr.: 46.333.591 von Jon_Schnee am 29.01.14 14:20:22

Super News

hier noch die Mutter von Obagi Medical Products:

Valeant Pharmaceuticals International
http://www.valeant.com/

Market
Capitalization:
$33.0B

Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multi-national specialty pharmaceutical company
that develops and markets prescription and non-prescription pharmaceutical products that make a meaningful
difference in patients’ lives. Valeant is focused on dermatology, eye health and niche therapeutic areas targeting
growth markets around the world.

mehr: http://valeant.q4web.com/files/doc_downloads/Valeant_Fact_Sh…

[Jon_Schnee]

Sirona Biochem Completes Global Exclusive Licensing Agreement with Obagi Medical Products


VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jan. 29, 2014) - Sirona Biochem Corp. (TSX VENTURE:SBM)(OTCQX:SRBCF)(FRANKFURT:ZSB) announced today the formal execution of the global exclusive licensing agreement with Obagi Medical Products (Obagi) for the commercialization of skin lightening compound TFC-849. Sirona Biochem will receive a licensing fee and ongoing royalty payments for global product sales from Obagi Medical Products.

Sirona will transfer its patented skin lightening technology and know-how to Obagi. Obagi will be responsible for the manufacturing, distribution and global sales of the final commercial products. Target launch of products including Sirona Biochem's TFC-849 is Q4 2014 for Obagi. The exclusive license for TFC-849 is valid for the global Valeant Pharmaceuticals family of companies.

"Obagi Medical Products is a premiere brand and provider of dermatological therapies worldwide," said Neil Belenkie, Chief Executive Officer of Sirona Biochem. "The skin lightening market, projected to reach $19.8 billion globally by 2018, provides an enormous commercial opportunity for both OMP and Sirona Biochem to provide safer, more effective therapies. We hope this is just the first of many opportunities to work with Obagi Medical Products and the Valeant Pharmaceutical family of companies."


About Obagi Medical Products

Obagi Medical Products, Inc. is a global specialty pharmaceutical company founded by leading skin care experts in 1988, and is owned by Valeant Pharmaceuticals International, Inc. Obagi products are designed to minimize the appearance of premature skin aging, skin damage, hyperpigmentation, acne, and sun damage and are primarily available through dermatologists, plastic surgeons, medical spas, and other skin care professionals.


About Sirona Biochem

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France. The company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds' efficacy and safety. Sirona Biochem's compounds are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem's wholly-owned French laboratory is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information visit www.sironabiochem.com.


About the Betaclear (Skin Lightening) Project

Sirona Biochem's French subsidiary TFChem received a $1.9 million grant in November 2011. This project is co-financed by the European Union and Europe Witnesses in Haute-Normandie with the support of the European Regional Development Fund (E.R.D.F.). A consortium of partners, including the University of Rouen (LMSM EA4312), contract research organization Biogalenys, and TFChem has been assembled to advance this project. The French government and European Union are looking to promote and initiate collaborative projects that are focused on the development of new products and services containing a high level of innovation.

Read more at http://www.stockhouse.com/news/press-releases/2014/01/29/sir…" target="_blank" rel="nofollow ugc noopener">http://www.stockhouse.com/news/press-releases/2014/01/29/sir…